Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer Q2 revenue rises 3% to $15.0 billion; reported loss on $4.3 billion impairments

Mixed Impact 4 of 5 earnings Written later

Pfizer reported second-quarter 2026 revenue of $15.0 billion, up 3% from a year earlier, and a reported loss of $0.04 per share, which reflects $4.3 billion in non-cash intangible asset impairments. Adjusted diluted EPS was $0.77, compared with $0.78 a year earlier. Pfizer raised its full-year 2026 revenue guidance midpoint by $500 million to a range of $60.5 to $62.5 billion and reaffirmed adjusted EPS guidance of $2.80 to $3.00, which absorbs an expected impact of about $0.10 from the Innovent Biologics transaction.

Key points

  • Q2 2026 revenue was $15.0 billion, up 3% reported and 1% operationally; reported loss per share was $(0.04) versus EPS of $0.51 a year earlier.
  • Full-year 2026 revenue guidance raised to $60.5 to $62.5 billion; adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00.
  • Pfizer announced $2.5 billion of additional anticipated productivity savings, expected to be realized from 2027 through 2029.
  • Pfizer is not planning share repurchases in 2026; $3.3 billion remains under its existing authorization.

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECAug 4, 2026, 7:02 AM ET
Accession number0000078003-26-000094

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.